The gross proceeds to the Company from the offering are expected to be approximately $4.3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The ...
Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering. Shares were down 27% to $3.03 in recent ...
Vivos Therapeutics shares rose on Wednesday after the company said its oral medical device for pediatric sleep apnea and snoring received 510(k) clearance from the Food and Drug Administration.
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos' DNA appliance now ...